ImmunoGen Stops Lung Cancer Trial, Shares Fall 20%.
Insights - ImmunoGen’s (IMGN) gave up most of this year’s gains when the company announced that it was stopping a phase 2 clinical trial of IMGN901 in … Continue Reading
Read nowAuthor Archives: Beth Senko, CFA
Endo Health to Expand by Buying Paladin Labs
Insights - Moving from target to hunter, Endo Health (ENDP) announced plans to purchase Paladin Labs (PLB.TO), a Canadian specialty pharmaceutical manufacturer, for $1.5 billion. Both companies … Continue Reading
Read nowMerck’s New HPV Vaccine Effective in Protecting Against 9 Types of HPV
Insights - In an important phase 3 trial, Merck’s (MRK) new investigational 9-valent Human Papilloma virus (HPV) vaccine, known as V503, compared favorably to the company’s current vaccine, … Continue Reading
Read nowWhose Teva is it Anyway?
Insights - Teva Pharmaceuticals (TEVA) announced Wednesday that its CEO, Jeremy Levin, has stepped down after a tumultuous 18-month tenure. The question now is how long will … Continue Reading
Read now